Healthcare

The report projects the market for AI in prior authorization (PA) to grow from $1.3B in 2025 to $5.6B by 2030, revolutionizing healthcare claims processing through automation, improved accuracy, and operational cost reduction. By 2030, AI will handle 72% of all PA submissions, boosting processing efficiency by 40%, reducing error rates by 25%, and lowering approval time by 30%. AI tools also cut fraud by 22% and save up to 50% in operational costs for health plans and providers, making AI-powered PA systems standard across major regions and setting new benchmarks for speed, reliability, and regulatory compliance.

This report analyzes the FemTech market penetration across the EU and Portugal (2025–2030), focusing on cultural barriers, reimbursement challenges, and consumer adoption. The FemTech market, which includes digital health solutions for women’s health, is expected to grow from €4.7B to €13.5B (CAGR 23%) by 2030. Key drivers include overcoming cultural stigmas, expanding reimbursement coverage, and increasing awareness of FemTech solutions for fertility, menstruation, menopause, and mental health. By 2030, Portugal will capture ~5% of the EU FemTech market share, as both public and private insurance begin to reimburse for FemTech-related products, improving access to care for women’s health.

This report explores hospital-at-home cybersecurity challenges, focusing on IoT device vulnerabilities and HIPAA compliance in North America and the USA (2025–2030). The market for hospital-at-home solutions is expected to grow from $9.2B in 2025 to $24.7B by 2030 (CAGR 21.9%). As more healthcare providers embrace remote patient monitoring and IoT-enabled medical devices, the risk of cybersecurity threats rises. By 2030, cybersecurity solutions for hospital-at-home models will account for 25% of the market, with a focus on IoT device protection, data encryption, and HIPAA-compliant systems. Increased patient data privacy concerns and regulatory scrutiny will drive investments in cybersecurity technologies to mitigate data breaches and ensure compliance with HIPAA regulations.

This report quantifies cannabis–drug interaction (CDI) alerting across Portugal and Europe (2025–2030), focusing on CYP450 enzyme pathways (CYP3A4, 2C9, 2C19, 2D6), EHR integration hurdles, and risk reduction economics. We model alert precision/recall, override rates, adverse drug event (ADE) avoidance, and time-to-alert in hospital and community settings. Results indicate CDI modules can cut cannabinoid-mediated ADEs 25–35%, raise prescriber adherence 18–24 points, and deliver ROI 19–27% when paired with structured cannabis intake capture, interoperable terminology, and tuned clinical decision support (CDS) thresholds.

This report quantifies cross-border health data governance in Europe (2025–2030), centered on GDPR, the European Health Data Space (EHDS), NIS2, eIDAS 2.0 wallets, and MyHealth@EU services (patient summary, ePrescription/eDispensation, lab results, imaging). We size spend on compliance tooling, interoperability platforms (FHIR/IHE), consent/pseudonymization, and sovereign cloud/edge. Benchmarks include cross-border exchange volume, time-to-access, data quality conformance, API uptime, and breach incidence. By 2030, pan-EU exchanges scale 5×, average access latency falls below 15 seconds, and compliant architectures deliver measurable ROI 17–24% through avoided litigation, faster care, and research reuse.

The report highlights GenAI’s expanding role in medical affairs, transforming scientific content creation, regulatory compliance, and operational efficiency across healthcare. GenAI solutions enable faster, more accurate medical documentation, automate literature reviews, and streamline scientific communications, while supporting stringent data privacy and compliance standards. Adoption of GenAI technologies is accelerating, addressing challenges such as bias, transparency, and integration with pharma workflows, and facilitating innovation in diagnostics, therapeutics, and medical research. By 2030, GenAI is set to redefine collaboration, regulatory adherence, and knowledge dissemination within life sciences and healthcare sectors.

Between 2025 and 2030, the commercialization of psychedelic therapies for mental health conditions accelerates in North America and Canada, with market growth from $2.1B to $10.4B (CAGR 36%). FDA approvals for psilocybin and MDMA increase, while Health Canada expands access under its Special Access Program (SAP). Integration into standard psychiatric care raises adoption rates, with 18% of clinics offering psychedelic-assisted therapy by 2030. Reimbursement pathways evolve with value-based models supported by growing clinical evidence, although regulatory hurdles and patient safety monitoring remain key challenges.

North American mRNA capacity is shifting from emergency surge to durable, repeatable supply. Between 2025 and 2030, drug-substance capacity expands from 2.4→6.8B doses (30-µg equivalent) and fill–finish from 1.9→5.5B doses. Utilization improves 58%→76% as demand normalizes to annual respiratory boosters, pediatrics, and rapid-update programs. OEE rises to 74–79%; batch success reaches ~97%, cutting release time to 8 days. COGS drops to ~$1.28/dose (ex-fill), and OTIF climbs to ~94% with colder, denser lanes. Competitive advantage accrues to multi-site networks marrying thermostable product, digital release, and orchestrated logistics.

This research examines 3D bioprinting regulatory frameworks in Europe from 2025 to 2030, focusing on quality control standards and commercialization timelines. The report explores how evolving regulations, safety protocols, and quality assurance frameworks will shape the adoption of 3D bioprinted tissues and organs. It provides insights into market growth, regulatory compliance, and expected time-to-market for commercial applications. The study is designed for biotech companies, regulators, and investors, highlighting the challenges and opportunities for commercializing 3D bioprinting technologies in Europe.

Between 2025 and 2030, patient-centric trial models redefine R&D in North America and Canada. Total clinical R&D expenditure grows from $49B to $88B (CAGR 12.4%), while decentralized and hybrid trials expand 26% → 72% of all new studies. Median enrollment time shortens 8.7 → 4.3 months, and minority participation rises 19% → 36%. AI-driven patient-matching algorithms improve screening efficiency +41%, while remote data capture reduces site cost −29%. Regulatory harmonization (FDA–Health Canada) enables cross-border participant interoperability and accelerates inclusion.